INTS Live signaler | Maksimer profitt med Getagraph.com

KJøP 123701 min ago

@ $3.41

Utstedt: 12 feb 2024 @ 20:19

Avkastning: 11.14%

Forrige signal: feb 8 - 18:41

Forrige signal: Selg

Avkastning: -5.28 %

Live Chart Being Loaded With Signals

Commentary (8 mai 2024 @ 17:09):

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors...

Stats
Dagens volum	4 668.00
Gjennomsnittsvolum	39 037.00
Markedsverdi	51.96M
EPS	$0 ( 2024-04-01 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.75
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-06	Wesolowski John M	Buy	25 000	Stock Option (right to buy Common Stock)
2024-03-06	Leahy Emer	Buy	50 000	Stock Option (right to buy Common Stock)
2024-03-06	Goldberg Mark A	Buy	50 000	Stock Option (right to buy Common Stock)
2024-03-06	Donovan Daniel	Buy	50 000	Stock Option (right to buy Common Stock)
2024-03-06	Bender Lewis H	Buy	464 805	Stock Option (right to buy Common Stock)

INSIDER POWER
57.37
Last 23 transactions
Buy: 803 379 \| Sell: 331 500

Intensity Therapeutics, Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Intensity Therapeutics, Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-147 000 (0.00 %)
EPS:	$-1.220

FY	2023
Omsetning:	$0
Bruttogevinst:	$-147 000 (0.00 %)
EPS:	$-1.220

FY	2022
Omsetning:	$0
Bruttogevinst:	$-179 037 (0.00 %)
EPS:	$-0.570

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.439

Financial Reports:

No articles found.

Intensity Therapeutics,

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.